I nuovi farmaci per HCV: frequenza della patologia, evidenze di efficacia e sicurezza, strategie di gestione. la pratica clinica
|
|
- Jane Newton
- 6 years ago
- Views:
Transcription
1 I nuovi farmaci per HCV: frequenza della patologia, evidenze di efficacia e sicurezza, strategie di gestione La revisione ii delle dll evidenze e indicazioni i iper la pratica clinica Marco Marzioni Segretario AISF
2 THE BURDEN OF HEPATITIS C IN ITALY The cause of death in at least persons each year The single etiologic agent in half the patients with cirrhosis The single etiologic agent in more than half the patients with a liver cancer The indication for liver transplantation in half the patients with ESLD Each year patients t with cirrhosis i or HCC hospitalized for 11 days on average, 50% HCV (SIS)
3 MULTIPLE DIRECT ATIVIRAL AGENTS 5 UTR 5UTR Core E 1 E2 p 7 NS2 NS3 4A NS4B NS5A NS5B 3 UTR HCV PIs Protease Viral enzyme Active site TVR BOC Simeprevir Fld Faldaprevir Asunaprevir ABT-450 MK-5172 Sovrapevir ACH-2684 NS5A inhibitors Non-enzyme Replication complex Daclatasvir Ledipasvir ABT-267 GS-5816 ACH-3102 PPI-668 GSK Samatasvir MK-8742 Polymerase NS5B NS5B Nucs Non Nucs Viral enzyme Viral enzyme Active site Allosteric site Sofosbuvir ABT-333 VX-135 Deleobuvir IDX20963 BMS ACH-3422 PPI-383 GS-9669 TMC647055
4 NOT ALL DIRECT-ACTING ANTIVIRALS ARE CREATED EQUAL Characteristic Protease Inhibitor * Protease Inhibitor ** NS5A Inhibitor Nuc Polymerase Inhibitor Non-Nuc Polymerase Inhibitor Resistance profile Pangenotypic efficacy Antiviral potency Adverse events Good profile Average profile Least favorable profile *First generation. **Second generation.
5 NEW DAAs AVAILABLE OVER THE NEXT MONTHS Timeline assumes: - EMA approval 3 months after FDA approval - AIFA reimbursement granted 9 months after EMA approval
6 RATIONALE FOR MOVING TO INTERFERON FREE REGIMENS IN TREATING HCV CHRONIC HEPATITIS Efficacy - IFN intolerant or ineligible - Specials populations Safety - Avoid hematologic, skin and psychiatric side effects Tl Tolerability - Reduced treatment duration - Small number of pills - High compliance expected Reduce the indirect costs - Clinicali l and biochemical i controls - Work absences Reduce the burden of the disease - If costs, availability and affordability of drugs will be optimal
7 AVAILABILITY OF NEW DAAs IN ITALY Often unpredictable Different criteria of reimbursement - Severe vs mild disease - Naïve vs experienced - Medical vs financial Different regional access to treatment Potential disparity among patients from different regions Progressive increase in warehousing effect
8 FACTORS INFLUENCING THE WAREHOUSING EFFECT Pro Low disease stage Low probability of SVR Inability to tolerate P/R Comorbidity Patient s preference Expectancy for newer regimens Cons Urgency of HCV clearance HCV related extrahepatic diseases
9 ABOUT COSTS. Physicians i must treatt the diseases with the most efficacious i drugs available The cost of drugs should not be the only parameter to be considered for their use The responsibility of the restriction of the resources at our disposal should not fall down on the physician The physician should use the treatment at a lower cost ONLY if this has been shown to have equal efficacy/tolerability profile compared to more expensive treatment
10 PROGNOSTIC MODELS TO ASSIST THERAPEUTIC ALLOCATIONS AND MEDICAL ETHICS IN A CONTEXT OF LIMITED RESOURCES EQUITY: the need to distribute equitably the therapeutic resources available INDIVIDUAL JUSTICE: the duty to promote the best interest of individual patients Medical urgency (treat first more advanced liver diseases) UTILITY: the duty to strive to obtain the best results for the correct population therapeutic use of the resource Post treatment outcomes: maximize SVR rates (number of treatments/number of SVR obtained) These values should be protected by means of good clinical practice through transparency and verifiability of the procedures and full traceability of individual clinical trial
11 EFFICACY AND SAFETY WORSEN IN ADVANCED LIVER DISEASE Proba ability of cure Utility system (F0-F2) F2) Urgency system (F3-F4-Dec.) F0 F1 F2 F3 F4 Severity of advers e events
12 SELECTION OF THE CANDIDATES TO RECEIVE NEW ANTIVIRALS All treatment-naïve and experienced patients with compensated liver disease due to HCV should be considered for therapy Priority F3-F4 Justified F2 Individualized F0-F1 ONLY IFN-free regimens decompensated, pre and post LT EASL recommendations on treatment of hepatitis C, J Hepatol, 2014.
13 SELECTION OF THE NEW ANTIVIRALS IN TREATING HCV GENOTYPE 1 INFECTED PATIENTS Patients without cirrhosis willing to receive IFN Naives and previous relapsers SOF + IFN + RBV for 12 wks (ideal for GT1a/b) SMV + IFN + RBV for 24 wks Exclude GT1a DCV + IFN + RBV for 24 wks Exclude GT1a No indications i to use first generation PIs (BOC or TVR) EASL recommendations on treatment of hepatitis C, J Hepatol, 2014, mod.
14 SELECTION OF THE NEW ANTIVIRALS IN TREATING HCV GENOTYPE 1 INFECTED PATIENTS Patients with comp. cirrhosis Naives and experienced SOF + SMV for 12 wks (ideal for GT1a/b) SMV + DCV for 12 wks (naives) or 24 (experienced) wks SOF + RBV for 24 wks Suboptimal No indications i to use first generation PIs (BOC or TVR) EASL recommendations on treatment of hepatitis C, J Hepatol, 2014, mod.
15 SELECTION OF THE NEW ANTIVIRALS IN TREATING HCV GENOTYPE 2 INFECTED PATIENTS All HCV GT2 infected patients SOF + RBV for 12 wks SOF + RBV for wks in experienced comp. cirrhotics EASL recommendations on treatment of hepatitis C, J Hepatol, 2014, mod.
16 SELECTION OF THE NEW ANTIVIRALS IN TREATING HCV GENOTYPE 3 INFECTED PATIENTS Patients without comp. cirrhosis Naives and experienced SOF + IFN + RBV for 12 wks SOF + RBV for 24 wks SOF + DCV for 12 wks (naives) or 24 wks (experienced) EASL recommendations on treatment of hepatitis C, J Hepatol, 2014, mod.
17 SELECTION OF THE NEW ANTIVIRALS IN TREATING HCV GENOTYPE 3 INFECTED PATIENTS Patients with comp. cirrhosis Naives and experienced SOF + IFN + RBV for 12 wks SOF + RBV for 24 wks (soboptimal) SOF + DCV + RBV for 24 wks (pending data)
18 WILL THERE STILL BE A ROLE FOR IFN DURING IN A IDEAL TREATMENT SCENARIO? Hard to cure GT3 DAA failures multi-daa resistant Prior non-responders Quad? Easy to cure IL28B CC high efficacy, short duration Asia? Mild disease option of IFN vs waiting for progression Cost containment Fewer or less effective DAAs GT2?
19 KEY CONCEPTS CONCERNING THE IDEAL SCENARIO FOR TREATMENT IN For the first time a real effective and safety options for treating patients with compensated severe liver disease is available The extension to access of patients with less severe liver disease to the tenew IFN free regimens e will be associated ated with wt expected SVR rates near to 90% Considering the imminent availability of the newest IFN-free antiviral regimens (ABT combinations, SOF+LDV, MK combinations) it could be expected that costs will be redefined
20 TREATMENT DECISIONS IN 2014 AND EARLY 2016: GENERAL CONSIDERATIONS Scientific treatment scenario is evolving rapidly Access to treatment probably will not follow this rapidity - Bureaucracy - Trading costs - Different region reimbursement criteria Considering efficacy and safety of new antivirals, treat now or defer can not be more decided taking into account only the costs but considering that patients should be cured with current and future regimens This will generate a huge gain in the future in terms of reduction of morbidity, mortality and hospitalization for liver disease only if the therapy will beavailable bl for themajority of patients t
21 And next?
22 How Many DAAs Do We Need? Assumptions: 1) Production of new virions = ~10 12 /day 2) HCV genome length = ~9600 nucleotides 3) Error rate = ~10-5 /per nucleotide copied Therefore, average number of changes/genome = 0.096/replication 096/ cycle # of Nucleotide Changes Probability # of Virions/Day x # of All Possible Mutants % of All Possible Mutants/Day x x x x x x x 10-5 If the theory is right: should need 3 DAAs Rong L, et al. Sci Transl Med. 2011;2:30-32.
23 DAA Options PI backbone potent/modest barrier PI + another low-barrier DAA (NNI/NS5A) for GT1b PI + 2 low-barrier DAAs for GT1a Nuc backbone potent/high barrier Nuc + low-barrier DAA for GT1a/b Nuc + PI Include ribavirin? May allow fewer DAAs (2 vs 3) May allow shorter therapy
24 Example of PI Backbone + NNI + RBV for GT1b Only Faldaprevir (PI) 120 mg QD + deleobuvir (NNI) 600 mg BID + RBV for 28 wks [1,2] (N = 78) Faldaprevir (PI) 120 mg QD + deleobuvir (NNI) 600 mg BID + RBV for 16 wks [3] (N = 32) SV VR12 (%) n/n = /22 6/8 31/37 9/11 1a Non-CC 1a CC 1b Non-CC HCV Subtype and IL28B GT 1b CC Simple regimen for GT1b only? VR12 (%) S n/n = /12 19/20 1a CC 1b HCV Subtype and IL28B GT 1. Zeuzem S, et al. NEJM. 2013;369: Zeuzem S, et al. EASL Abstract Dufour JF, et al. AASLD Abstract 1102.
25 Example of PI Backbone + NS5A in Prior Null Responders Daclatasvir (NS5A) + Asunaprevir (PI) x 24 wks Daclatasvir (NS5A) + Asunaprevir (PI) + BMS (NNI) x 12 wks 100 Japan [2] (GT1a) Treatment naive [3] 96 (GT1b), or 24 (% %) SVR4, United States [1] 36 n/n = 4/11 9/10 121/133 27/28 0 Likely adequate for GT1b but not for GT1a Overcome by addition of third drug: only 12 wks US study 9/11 GT1a Japanese study 10/10 GT1b 1. Lok AS, et al. N Engl J Med. 2012;366: Chayama K, et al. Hepatology. 2012;55: Everson G, et al. AASLD Abstract LB-1.
26 Example of PI Backbone + 2 Other DAAs ABT-450/RTV (PI) ± ABT-333 (NNI) + ABT-267 (NS5A) ± RBV x 12 wks SV VR12 (%) Treatment-Naive Patients Null Responders n = a 1b 1a 1b 1a 1b 1a 1b 1a 1b 1a 1b ABT-450 ABT-450 ABT-450 ABT-450 ABT-450 ABT-450 ABT-333 RBV ABT-267 RBV ABT-267 ABT-333 ABT-267 ABT-333 RBV ABT-267 RBV ABT-267 ABT-333 RBV 5 drugs (3 pills) but 12 weeks, one size fits all Observed data (above bar) ITT (within bar) Kowdley KV, et al. AASLD Abstract LB-1.
27 Example of PI Backbone + NS5A in GT1b Trt-Naive Pts and Nulls (PEARL-1) ABT-450/RTV (PI) + ABT-267 (NS5A) for 16 wks (N = 32) SVR12 (%) Lawitz E, et al. AASLD Abstract /42 36/40 0 Naives Nulls
28 SAPPHIRE Phase III Studies: PI Backbone + 2 Other DAAs SAPPHIRE-1: GT1 treatment-naive SAPPHIRE-2: GT1 treatment-experienced noncirrhotic patients: noncirrhotic patients (49% null responders): ABT-450/RTV/ABT-267 FDC ABT-450/RTV/ABT-267 FDC + ABT RBV for 12 wks + ABT RBV for 12 wks SVR12 (%) n/n = / / / 151 SVR12 (%) n/n = 0 Overall GT1a GT1b Overall GT1a GT1b Press release. These data are available in press release format only, have not been peer reviewed, may be incomplete, and we await presentation or publication in a peer-reviewed format before conclusions should be made from these data / / / 123
29 Exception to the Rule: C-WORTHY: PI + NS5A ± RBV in Treatment-Naive GT1 HCV C-WORTHY: MK-5172 (PI) + MK-8742 (NS5A) ± RBV for 12 wks patients with GT1a randomized 1:1 to RBV arms only; patients t with GT1b randomized d 1:1:2 1 into all 3 arms MK mg + MK mg + RBV (n = 25) SVR12 (% %) n/n = 24/25 24/27 13/13 MK mg + MK mg + RBV (n = 27) MK mg + MK mg (n = 13) Lawitz E, et al. AASLD Abstract 76.
30 What About a Nuc Backbone?
31 Example of Nuc Backbone + PI in Trt-Naive Pts and Nulls (COSMOS) 78% GT1a 50% Q80K 94% non-cc All nulls SMV (PI) + SOF (Nuc) + RBV 12 wks SV VR12 (%) / / 14 F0-F2 Fibrosis SV VR4 (%) SMV (PI) + SOF (Nuc) 12 wks 96 26/ / 14 F3/F4 Fibrosis 78% GT1a 40% Q80K 79% non-cc 47% F4 54% Null Major caveats: small n, no plan for phase III trial Jacobson I, et al. AASLD Abstract LB-3.
32 Another Option: Nuc Backbone + NS5A SOF (Nuc) + daclatasvir (NS5A) ± RBV x 24 wks SOF (Nuc) + daclatasvir (NS5A) ± RBV x 12 wks SVR4 or 12 (% %) /14 15/15 40/41 39/41 DCV + SOF DCV + SOF DCV DCV + SOF + RBV + SOF + RBV 24 wks 12 wks Major caveats: small n, no plan for phase III trial Sulkowski M, et al. AASLD Abstract LB-2.
33 1-Pill Version of Nuc + NS5A LONESTAR: SOF (Nuc) + ledipasvir (NS5A) FDC ± RBV Treatment-naive patients (noncirrhotic) PI failures (50% cirrhotic) SV VR4 or 12 (%) /20 21/21 18/19 18/19 21/21 SOF/LDV SOF/LDV SOF/LDV SOF/LDV SOF/LDV +RBV +RBV 8 wks 12 wks 12 wks No breakthrough; 2 relapses, both without RBV 1 case of resistance retreated with SOF/LDV + RBV x 24 weeks SVR Lawitz E, et al. AASLD Abstract 215.
34 Phase III Studies of Sofosbuvir (Nuc) + Ledipasvir (NS5A) ± RBV in GT1 HCV ION-1*: GT1 treatment-naive pts (16% cirrhotic): SOF/LDV FDC ± RBV for 12 wks ION-3: GT1 treatment-naive pts: SOF/LDV FDC ± RBV for 8 or 12 wks ION-2: GT1 treatment-experienced pts (20% cirrhotic): SOF/LDV FDC ± RBV for 12 or 24 wks SOF/LDV FDC SOF/LDV FDC + RBV SVR12 (%) n/n = / / Wks 202/ / / / / / / 111 8Wks 12 Wks 12 Wks 24 Wks *24-wk arms not yet reported. Press release. These data are available in press release format only, have not been peer reviewed, may be incomplete, and we await presentation or publication in a peer-reviewed format before conclusions should be made from these data.
35 What About Resistance? NS5A:L31M 25.5% NS5B:No RAVs HCV RNA (l log 10 IU/m ml) NS5A:Q30L (4.50%) L31M (> 99%) Y93H (96.74%) NS5B:S282T (91.24%) SOF/LDV 8 Wks NS5A:Q30L (3.47%) L31M (94.38%) L31V (4.67%) Y93H (98.19%) NS5B:S282T (8.00%) Retreatment: SOF/LDV + RBV 24 Wks SVR12 Posttreatment Posttreatment LLOQ-TD LLOQ-TND Lawitz E, et al. AASLD Abstract 215.
36 What about GT2 and GT3?
37 Sofosbuvir + RBV for GT2 and GT3 HCV: Approved Indications All GT2 patients receive same regimen, regardless of previous treatment history or fibrosis level 12 weeks Sofosbuvir + RBV All GT3 patients receive same regimen, regardless of previous treatment history or fibrosis level 24 weeks Sofosbuvir + RBV If drugs combined with sofosbuvir must be permanently discontinued, sofosbuvir should also be discontinued Sofosbuvir [package insert]. December 2013.
38 FUSION: SVR by GT and Cirrhosis i in Treatment-Experienced Patients Sofosbuvir + RBV 12 wks Sofosbuvir + RBV 16 wks SVR12 (% %) / 23/ 14/ 25/ 14/ n/n = /10 7/ / No Cirrhosis Cirrhosis No Cirrhosis Cirrhosis GT2 GT3 SVR12 (% %) 12 weeks sufficient for GT2 16 weeks better than 12 weeks for GT3 so what about 24 weeks? Jacobson IM, et al. N Engl J Med. 2013;368:
39 VALENCE: Efficacy With 24-Week Sofosbuvir Plus Ribavirin in GT3 Patients SV R12 (%) n/n = 0 Treatment Naive [1] Treatment Experienced [1] / 92 No Cirrhosis 12/ 13 Cirrhosis 87 87/ / 45 R12 (%) SV n/n = FUSION [2] 0 24 Wks 24 Wks 16 Wks 24 weeks better for treatment-naive patients Not ideal for cirrhotic treatment failures 61 14/ Zeuzem S, et al. AASLD Abstract Jacobson IM, et al. N Engl J Med. 2013;368:
40 Do We Still Need IFN for GT3? LONESTAR-2: SOF + PegIFN + RBV x 12 wks No cirrhosis Cirrhosis VR12 (% %) S / 9 13/ 14 10/ 12 10/ 12 0 GT 2 GT 3 Small single-center study but looks promising... IFN is not dead yet! Lawitz E, et al. AASLD Abstract LB-4. 85% previous treatment failures
41 Different Strategies Cost Overtreatment of some Tailored Fewest regimen Priorities drugs for each fits all population Simplicity One size Pi Primary care Shortest duration
Hepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More informationWill difficult-to-treat patients remain difficultto-treat. generation of treatments?
Will difficult-to-treat patients remain difficultto-treat with the new generation of treatments? Jordan J Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationHepatitis C: Aplicaciones Clínicas de la Resistencia. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña
Hepatitis C: Aplicaciones Clínicas de la Resistencia Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña DAA agents approved or in more advanced stages of clinical
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationNS5A inhibitors: ideal candidates for combination?
NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang
More informationThe Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago
The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years Nancy Reau, MD Associate Professor University of Chicago Learning Objectives Upon completion of this presentation, learners should
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationHCV disease: treatment or deferral? Antonio Craxì Gastroenterologia & Epatologia, Di.Bi.M.I.S., Università di Palermo
HCV disease: treatment or deferral? Antonio Craxì Gastroenterologia & Epatologia, Di.Bi.M.I.S., Università di Palermo antonio.craxi@unipa.it Key factors in deciding to treat or wait Patient factors Urgency
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationEASL and The Future of HCV Treatment
EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationMassimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda
Massimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda Innovative strategies in viral hepatitis : Hepatitis C: Interferon and/or Ribavirin free regimens 10th International Workshop on
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationInterferon Side Effects and The Future of Interferon Sparing Regimens. Todd Wills, MD ETAC Infectious Disease Specialist
Interferon Side Effects and The Future of Interferon Sparing Regimens Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL FEBRUARY 15,
More informationEd Gane NZ Liver Transplant Unit Auckland City Hospital
Clinical Management of Hepatitis C Patients Treat Now or Wait Ed Gane NZ Liver Transplant Unit Auckland City Hospital SVR24 rates with PEG/RBV by HCV genotype Data from the real-world PROPHESYS cohort
More informationTreatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy
Treatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy antonio.craxi@unipa.it Ad Board and grants: Abbvie, Achillion, BristolMyers Squibb,
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationNew Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationHCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD
HCV: The next 18 months David L. Wyles, M.D. Associate Professor of Medicine UCSD FIRST, A LOOK BACK WHAT DID I SAY LAST YEAR? My predictions for genotype 1: Multiple highly efficacious, well-tolerated,
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationWhat do we need to know about RAVs clinically?
14 th European HIV & Hepatitis Workshop Rome, 25-27 May, 2016 What do we need to know about RAVs clinically? Stefan Zeuzem, MD University of Frankfurt Germany Background Resistance associated variants
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationResistencias & Epidemiología. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña
Resistencias & Epidemiología Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Rapid Evolution of HCV Regimens: Easier to take/tolerate, Short Duration, Pangenotypic,
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationHighlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases
Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with
More informationNovember 2013 AASLD Investor Event 4 November
November 2013 AASLD Investor Event 4 November Maris Hartmanis, President and CEO Charlotte Edenius, EVP Development Bertil Samuelsson, CSA Rein Piir, EVP Corporate Affairs & IR Corporate presentation,
More informationClinical Applications of Resistance Stuart C. Ray, MD
Clinical Applications of Resistance Stuart C. Ray, MD Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Training Program Johns Hopkins University School of Medicine Disclosures
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationDavid L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
FORMATTED: 1/3/16 Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? Atlanta, Georgia: October 2, 216 David L. Wyles, MD Chief, Division of Infectious Disease Denver Health
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationTerapie attuali. Eradicazione di HCV e nuove prospettive:
Eradicazione di HCV e nuove prospettive: Terapie attuali Luisa Pasulo U.S.C. Gastroenterologia Epatologia e Trapiantologia Ospedale Papa Giovanni XXIII - Bergamo From Infection to liver disease Infezione
More information9/21/2014. Sarah Naidoo, PharmD, BCPS September 26, 2014
Sarah Naidoo, PharmD, BCPS September 26, 2014 Be able to discuss changes in hepatitis C treatment Be able to provide recommendations to providers regarding hepatitis C treatment Be able to provide patient
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationO. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki
O. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki Disclosures Advisory Board: Abbvie Pharmaceuticals Speaker: Gilead Sciences, Bristol-Myers Squibb Research
More informationHCV Drug Resistance: Regulatory Perspective
HCV Drug Resistance: Regulatory Perspective Patrick Harrington, PhD Senior Clinical Virology Reviewer Division of Antiviral Products, FDA/CDER 2016 HIV and Hepatitis Clinical Pharmacology Workshop Washington,
More informationMassimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future
Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationThe Egyptian Plan to Cure HCV
The Egyptian Plan to Cure HCV Gamal Esmat Professor of Endemic Medicine & Hepatology Vice President of Cairo University for Graduate Studies and Research Disclosure Advisory Committee Board Member : MSD,
More information10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado FORMATTED: 1/3/16
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 1)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Goals for Hepatitis C Therapy Compared to PegIFN/RBV, new products should offer: Improved efficacy Efficacy in all patient types including
More informationTransformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
More informationHBV/HCV Eradication. Prof. Jean-Michel Pawlotsky, MD, PhD
HBV/HCV Eradication Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationManagement of HCV Tawesak Tanwandee
Management of HCV 2016 Tawesak Tanwandee Topics Burden of HCV in our countries Natural history and unmet need for HCV treatment Current treatment as for 2016 Conclusion Evolution from HCV infection to
More informationUpdates in the Management of HCV: What Clinicians Who Care for Patients With HCV Need to Know Today
Updates in the Management of HCV: What Clinicians Who Care for Patients With HCV Need to Know Today The treatment paradigm for hepatitis C virus (HCV) is changing very rapidly. In the short time since
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationHepatitis C en 2013 Tratar o Esperar? Vicente Soriano Servicio de Enfermedades Infecciosas Hospital Carlos III Madrid
Hepatitis C en 2013 Tratar o Esperar? Vicente Soriano Servicio de Enfermedades Infecciosas Hospital Carlos III Madrid Caveats on hepatitis C therapy decision making We treat persons with a liver. They
More informationFailure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016
Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16 Disclosures Board member for : Schering-Plough,
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More information